Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07261631). This is a study registration, not published results. Lead sponsor: Novartis Pharmaceuticals. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 180 participants (ESTIMATED). Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma. Interventions: DRUG: 68Ga-NNS309; DRUG: 177Lu-DFC413. Primary outcome measures: Incidence and severity of dose limiting toxicities of 177Lu-DFC413 , Within first treatment cycle, up to maximum 6 weeks; Incidence and severity of adverse events and serious adverse events of 177Lu-DFC413 , From study treatment start up to approximately 42 months; Dose modifications for 177Lu-DFC413 , From study treatment start until last dose of study treatment, assessed up to approximately 24 weeks; Dose intensity for 177Lu-DFC413 , From study treatment start until last dose of study treatment, assessed up to approximately 24 weeks. Brief summary: The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors